Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics (DSGN)
NASDAQ:DSGN
Holding DSGN?
Track your performance easily
DSGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.96 - $6.91
Previous Close$5.83
Volume161.25K
Average Volume (3M)237.30K
Market Cap
$327.83M
Enterprise Value$75.50M
Total Cash (Recent Filing)$254.07M
Total Debt (Recent Filing)$1.74M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Mar 06, 2025EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding56,620,525
10 Day Avg. Volume100,829
30 Day Avg. Volume237,303
Standard Deviation0.23
R-Squared0.15
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$4.00Price Target Upside-31.39% Downside
Rating ConsensusHold
Number of Analyst Covering1
Design Therapeutics News
PremiumCompany Announcements
Design Therapeutics Reports Strong Q3 and Pipeline Progress
PremiumPre-Earnings
Is DSGN a Buy, Before Earnings?
Ownership Overview
19.36% Insiders
6.36% Mutual Funds
1.35% Other Institutional Investors
67.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DSGN FAQ
What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $1.96 and its highest was $6.91 in the past 12 months.
What is Design Therapeutics’s market cap?
Currently, no data Available
When is Design Therapeutics’s upcoming earnings report date?
Design Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 116 days.
How were Design Therapeutics’s earnings last quarter?
Design Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.013.
Is Design Therapeutics overvalued?
According to Wall Street analysts Design Therapeutics’s price is currently Overvalued.
Does Design Therapeutics pay dividends?
Design Therapeutics does not currently pay dividends.
What is Design Therapeutics’s EPS estimate?
Design Therapeutics’s EPS estimate is -$0.27.
How many shares outstanding does Design Therapeutics have?
Design Therapeutics has 56,620,525 shares outstanding.
What happened to Design Therapeutics’s price movement after its last earnings report?
Design Therapeutics reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went up 0.691%.
Which hedge fund is a major shareholder of Design Therapeutics?
Among the largest hedge funds holding Design Therapeutics’s share is Baker Bros Advisors LP. It holds Design Therapeutics’s shares valued at 6M.
---
Design Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (-31.39% Downside)
$4.00 (-31.39% Downside)
Hedge Fund Trend
Increased
By 33.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
185.78%
12-Months-Change
Fundamentals
Return on Equity
-17.78%
Trailing 12-Months
Asset Growth
-13.49%
Trailing 12-Months
Company Description
Design Therapeutics
Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.
---
DSGN Earnings Call
Q4 2024
0:00 / 0:00
---
DSGN Stock 12 Month Forecast
Average Price Target
$4.00
▼(-31.39% Downside)
Technical Analysis
Best Analysts Covering DSGN
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-44.58%
upgraded a buy rating 6 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -44.58% per trade.
---